Impact and Predictors of Paravalvular Regurgitation Following Implantation of the Fully Repostionable and Retrievable Lotus Transcatheter Aortic Valve: Results From the Reprise III Randomized Controlled Trial
Files
Download Full Text
Publication Date
3-2018
Keywords
cards
Disciplines
Cardiology
Abstract
Background
Paravalvular leak (PVL) following TAVR has been associated with worse long-term outcomes including an increased risk of mortality. REPRISE III was a large randomized trial comparing 2 contemporary TAVR devices: Lotus and CoreValve (CV). Lotus incorporates an adaptive seal designed to minimize PVL. In this analysis, we evaluated the predictors of PVL and its impact on clinical outcomes.
Methods
Patients with high/extreme surgical risk and severe, symptomatic aortic stenosis underwent randomization to Lotus or CV. Multivariate modeling to assess predictors of PVL and outcomes stratified by PVL at 30 days were evaluated.
Results
We randomized 912 patients (2 Lotus:1 CV), age 83±7 years, 51% female, and Society of Thoracic Surgeons predicted risk of mortality 6.8%±4.0%. Lotus was superior to CV for the secondary endpoint of ≥moderate PVL at 1 year (Lotus 0.9%, CV 6.9%; p
Conclusion
Rates of PVL with the Lotus valve were lower than with CV. Calcium was a strong predictor of PVL. Overall, outcomes were similar between groups at 1 year though longer-term follow-up is needed.
Area of Special Interest
Cardiovascular (Heart)
Specialty/Research Institute
Center for Cardiovascular Analytics, Research + Data Science (CARDS)
Specialty/Research Institute
Cardiology
Conference / Event Name
American College of Cardiology Annual Scientific Session & Expo
Location
Orlando, FL
DOI
DOI: 10.1016/S0735-1097(18)31966-1
